Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer

Breast Cancer Res Treat. 1994;32(2):229-33. doi: 10.1007/BF00665774.

Abstract

Previous studies suggest a prognostic role for PDGF in patients with breast cancer, with patients with high plasma PDGF levels or positive response to therapy. We have examined a further 58 patients with advanced breast cancer for the presence of tissue PDGF immunostaining. Patients displaying positive tissue immunostaining for PDGF had a highly significant shorter survival (p = 0.002) than patients with no immunostaining. In addition PDGF positive patients treated with combination chemotherapy had a significantly lower response rate (p = 0.05) than PDGF negative patients. These results confirm our previous findings that PDGF may be an important indicator of shortened survival and treatment failure in patients with advanced breast cancer.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / analysis*
  • Breast Neoplasms / chemistry*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology
  • Female
  • Hormones / therapeutic use
  • Humans
  • Ki-67 Antigen
  • Life Tables
  • Menopause
  • Middle Aged
  • Neoplasm Proteins / analysis*
  • Nuclear Proteins / analysis
  • Platelet-Derived Growth Factor / analysis*
  • Prognosis
  • Receptors, Estrogen / analysis
  • Receptors, Progesterone / analysis
  • Skin Neoplasms / chemistry
  • Skin Neoplasms / pathology
  • Skin Neoplasms / secondary
  • South Africa / epidemiology
  • Survival Analysis
  • Transforming Growth Factor beta / analysis

Substances

  • Biomarkers, Tumor
  • Hormones
  • Ki-67 Antigen
  • Neoplasm Proteins
  • Nuclear Proteins
  • Platelet-Derived Growth Factor
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Transforming Growth Factor beta